Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024... Show more
FMS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on May 30, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for FMS moved out of overbought territory on May 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on FMS as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
FMS broke above its upper Bollinger Band on May 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FMS advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 246 cases where FMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.762) is normal, around the industry mean (4.650). P/E Ratio (20.797) is within average values for comparable stocks, (71.885). FMS's Projected Growth (PEG Ratio) (0.452) is slightly lower than the industry average of (1.595). Dividend Yield (0.030) settles around the average of (0.025) among similar stocks. P/S Ratio (0.533) is also within normal values, averaging (9.268).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
a manufacturer of renal and dialysis products
Industry MedicalNursingServices
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
IAUM | 33.65 | 0.21 | +0.63% |
iShares® Gold Trust Micro | |||
GDMA | 33.45 | 0.14 | +0.43% |
Gadsden Dynamic Multi-Asset ETF | |||
VOE | 161.67 | -0.89 | -0.55% |
Vanguard Mid-Cap Value ETF | |||
TXS | 33.74 | -0.25 | -0.72% |
Texas Capital Texas Equity Index ETF | |||
CDL | 65.39 | -0.57 | -0.86% |
VictoryShares US LgCp Hi Div Vol Wtd ETF |
A.I.dvisor indicates that over the last year, FMS has been loosely correlated with FSNUY. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if FMS jumps, then FSNUY could also see price increases.
Ticker / NAME | Correlation To FMS | 1D Price Change % | ||
---|---|---|---|---|
FMS | 100% | -0.42% | ||
FSNUY - FMS | 52% Loosely correlated | +1.09% | ||
DVA - FMS | 37% Loosely correlated | +0.56% | ||
DNTCF - FMS | 35% Loosely correlated | -0.31% | ||
CHE - FMS | 28% Poorly correlated | -1.19% | ||
OPCH - FMS | 28% Poorly correlated | -1.23% | ||
More |